Ardelyx, Inc.
NASDAQ:ARDXBiotechnology
-$0.06 today
- Market cap
- $784.28M
- Beta
- 0.58
- P/E (TTM)
- -24.5
- EPS (TTM)
- -$0.24
Volume 4.75M
Average 3.58M
ARDX Debt Repayment
Cash used to repay borrowings during the period.
Ardelyx, Inc.NASDAQ: ARDX
Debt Repayment · Q1 FY2026 · quarter ended Mar 2026
Debt repayment outflow grows to $0
Q1 FY2026 debt repayment was $0, compared with $0 a year earlier. Trailing-twelve-month debt repayment was $48.67M.
Context
- Debt repayment amounted to 11.9% of revenue in FY2025, down 17.9 pp from a year earlier.
- Debt repayment increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly debt repayment holds near $0 or moves back toward the trailing-twelve-month quarterly average of $12.17M.
Sources:Cash FlowText generated from reported figures; not investment advice.
Debt Repayment history
USD · from the cash flow
- Latest · FY2025
- 48.67M USD
- Year-over-year change
- -51.1%
| Period | Period end | Debt Repayment | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 48.67M | -51.1% |
| FY2024 | 2024-12-31 | 99.45M | +344.3% |
| FY2023 | 2023-12-31 | 22.39M | +469.0% |
| FY2022 | 2022-12-31 | (6.07M) | +68.8% |
| FY2021 | 2021-12-31 | (19.44M) | — |
Debt Repayment vs competitors
How ARDX compares with its peers on the latest reported figures
- ARDX's LTM Mar 2026 debt repayment of $48.67M is the largest of the 5 companies compared; the peer median is $4.58M.
- Its year-over-year change of -0.1% is the 2nd highest of 4, against a peer median of -8.8%.
- Debt repayment amounts to 11.4% of revenue for ARDX, versus a peer median of 2.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $48.67M | -0.1% | — | 11.4% | |
| LTM Mar 2026 | $38.52M | +342.0% | — | 192.6% | |
| LTM Mar 2026 | $9.17M | — | -55.3% | 2.9% | |
| LTM Mar 2026 | $5.99M | -137.7% | — | 2.6% | |
| LTM Mar 2026 | $10.03K | -8.8% | +18.6% | — | |
| Peer median (excluding ARDX) | $4.58M | -8.8% | -18.4% | 2.9% | |
Competitors are the stored peer set for ARDX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (158.17M) | (67.21M) | (66.07M) | (39.14M) | (61.6M) |
| Depreciation & Amortization | 1.44M | 1.14M | 1.29M | 2.06M | 3.06M |
| Deferred Income Tax | (190K) | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 12.04M | 10.75M | 13.53M | 37.38M | 48.96M |
| Change in Working Capital | (11.92M) | (19.58M) | (43.39M) | (49.17M) | (31.35M) |
| Accounts Receivables | (502K) | (7.23M) | (14.3M) | (35.67M) | (14.14M) |
| Inventory | (10.37M) | (28.35M) | (21.14M) | (41.7M) | (31.92M) |
| Accounts Payables | (1.35M) | 6.58M | 279K | 4.86M | 3.24M |
| Other Working Capital | 300K | 9.42M | (8.23M) | 23.34M | 11.48M |
| Other Non-Cash Items | 4.25M | 4.84M | 4.91M | 4.05M | (1.55M) |
| Operating Cash Flow | (152.55M) | (70.04M) | (89.72M) | (44.81M) | (42.48M) |
| Capital Expenditures | (1.87M) | (55K) | (344K) | (1.01M) | (1.49M) |
| Acquisitions (Net) | (52.82M) | 0 | 0 | 0 | 0 |
| Purchases of Investments | (72.74M) | (50.33M) | (215.23M) | (195.16M) | (218.92M) |
| Sales of Investments | 125.55M | 67M | 84.32M | 177.85M | 211.46M |
| Other Investing Activities | 52.82M | 1.8M | 0 | 0 | 0 |
| Investing Cash Flow | 50.95M | 18.42M | (131.25M) | (18.32M) | (8.96M) |
| Debt Repayment | (19.44M) | (6.07M) | 22.39M | 99.45M | 48.67M |
| Common Stock Issued | 101.15M | 71.63M | 119.24M | 8.14M | 5.84M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 1.3M | 9.78M | 4.67M | (1M) | 0 |
| Financing Cash Flow | 83M | 75.34M | 146.3M | 106.59M | 54.51M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (18.6M) | 23.71M | (74.67M) | 43.46M | 3.07M |
| Free Cash Flow | (154.42M) | (70.1M) | (90.06M) | (45.82M) | (43.98M) |
Ardelyx, Inc.
NASDAQ:ARDX
Intrinsic Alpha fair value
Locked
Current Price
$3.12
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.